Peritoneal Cancer

These findings establish KAP1 as a critical driver of tumor progression in GAC through YAP1 regulation and HNRNPAB interaction, highlighting its potential therapeutic target. This study advances our understanding and offers a preclinical framework to improve outcomes for GAC.

P=N/A, N=240, Recruiting, Dana-Farber Cancer Institute | Not yet recruiting --> Recruiting

P1, N=12, Recruiting, Zhejiang University

CONCLUSIONS This case illustrates a rare instance of recurrent SBT with metastasis to the quadratus lumborum muscle. Given the exceptionally slow progression of recurrent SBT, long-term follow-up with CT imaging and serum CA125 monitoring is crucial for timely intervention and appropriate management upon recurrence.

P2, N=0, Withdrawn, University Hospital Tuebingen | N=46 --> 0 | Unknown status --> Withdrawn

P2, N=22, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting

This review examines the current status of molecular pathology studies, recent evidence on the clinical implications of STIC, new data on the use of opportunistic salpingectomy, and published patient outcomes since then. The question of whether the potential benefit of opportunistic salpingectomy, outweighs the potential harms associated with surgical morbidity, which have not been conclusively excluded, should be revisited in light of these recent data.

P1, N=40, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Feb 2026 | Trial primary completion date: Dec 2024 --> Feb 2026

P1, N=20, Completed, Erasmus Medical Center | Active, not recruiting --> Completed

One patient under active surveillance was diagnosed with peritoneal carcinomatosis 5 years after initial diagnosis of STIC whereas none recurred in the chemotherapy group. The wide variety of treatment approaches we observed highlights a need for more data on this entity to support management guidelines.

P=N/A, N=80, Recruiting, Jules Bordet Institute | Phase classification: P2 --> P=N/A

P2, N=20, Recruiting, University of California, Davis | Trial completion date: Jul 2027 --> Mar 2027 | Trial primary completion date: Apr 2026 --> Dec 2025

She initially had headaches managed with ibuprofen...Given the rarity of PPCCC, our case highlights how increased clinical vigilance and prompt multidisciplinary efforts are essential for an accurate diagnosis, especially in younger patients to not delay management. Currently, there are no established management guidelines; however, initial treatment with surgical debulking followed by chemotherapy is often practiced.

This case underscores the need to consider peritoneal tuberculosis in the differential diagnosis of young women with adnexal masses, ascites, and elevated CA-125 levels in endemic regions. Early histopathological confirmation via minimally invasive laparoscopy can avert unnecessary surgery and enable timely treatment.

P3, N=300, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting

P2, N=140, Not yet recruiting, AbbVie

P=N/A, N=30, Active, not recruiting, Laval University | Trial completion date: Dec 2025 --> Sep 2025

P=N/A, N=40, Completed, Laval University | Active, not recruiting --> Completed | Trial completion date: Jun 2025 --> Sep 2024 | Trial primary completion date: Dec 2024 --> Mar 2024

P4, N=89, Terminated, North Eastern German Society of Gynaecological Oncology | Completed --> Terminated; A total of 204 patients were planned to be randomized. Due to slow recruitment of the trial, the recruitment was prematurely terminated after randomization of the 89th patient.

P=N/A, N=0, Withdrawn, Pfizer | N=400 --> 0 | Not yet recruiting --> Withdrawn

P1/2, N=12, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | N=75 --> 12

These data highlight the need for caution in antibody selection when developing immunohistochemistry-based assays, as some antibodies failed to cleanly and specifically identify FRα expression. We identified 2 antibodies appropriate for further investigation; however, as developed, these antibodies may overselect patients for treatment with FRα-targeted therapies.

It is difficult to observe the upper abdomen in laparotomic RRSO, whereas laparoscopy allows for visualization of the entire abdominal cavity and a shorter operative time; therefore, laparoscopic surgery is considered a viable option. Post-RRSO patient management requires follow-up to monitor for the development of peritoneal cancer, and in premenopausal women in particular, treatment and follow-up for any symptoms of menopause are needed; therefore, individualized care is required.

P=N/A, N=28, Recruiting, Mayo Clinic

P2, N=61, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2025 --> Feb 2026

Given the tumor's limited sensitivity to chemotherapy, she was treated with neoadjuvant endocrine therapy (ET) using fulvestrant, palbociclib, and leuprolide. This case supports the potential role of endocrine-based targeted therapy in managing pediatric LGSOC, offering a viable alternative for patients with limited treatment options. Further research is needed to optimize treatment strategies and improve survival outcomes in this rare population.

P3, N=166, Not yet recruiting, Jina Pharmaceuticals Inc.

P1, N=50, Recruiting, Bio-Path Holdings, Inc. | Trial completion date: Oct 2024 --> Oct 2027 | Trial primary completion date: Jul 2024 --> Jul 2027

P1/2, N=22, Recruiting, Case Comprehensive Cancer Center | Trial completion date: Feb 2025 --> Aug 2025 | Trial primary completion date: Feb 2025 --> Aug 2025

P2/3, N=444, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Sep 2026

P1, N=50, Not yet recruiting, University of Colorado, Denver

P=N/A, N=120, Not yet recruiting, Roswell Park Cancer Institute

P1/2, N=155, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2025 --> Feb 2026

Single cell profiling of AC-PC pairs reveals dedifferentiation from mucinous differentiated states in primary AC into intestinal stem cell and fetal progenitor states in AC-PC, with upregulation of oncogenic signaling pathways. Through hypothesis-driven drug testing, we identify KRAS MULTI -ON inhibitor RMC-7977 and Wnt-targeting tyrosine kinase inhibitor WNTinib as novel, clinically actionable strategies to target AC-PC more effectively.

P3, N=468, Not yet recruiting, Hansoh BioMedical R&D Company

Preoperative assessment of symptoms and histopathology, PCI and a complete CRS combined with tumor markers CEA, CA19-9 and CA125 are independent prognostic indicators for selection by the multidisciplinary team of CRC PM patients for CRS and HIPEC. All three tumor markers are needed for a meaningful assessment.

P1, N=25, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2025 --> Feb 2026

P1, N=24, Not yet recruiting, Shanghai Gynecologic Oncology Group

P2, N=73, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Jan 2025 --> May 2025

In summary, the results demonstrate substantial agreement and high accuracy of the NGS-based GS Focus HRD test compared to MyChoice® HRD Plus CDx. Our in-house assay is eligible for diagnostic test approval and market access as per Brazilian regulations.

Median survival was 21 months for paclitaxel + platinum derivatives (PC), 27 months for PC + bevacizumab (BEV), and 30 months for PC + BEV + PARPi. However, variations in financial regulations and drug accessibility persist across countries. Despite these challenges, physicians should prioritize the most effective therapies available.

The initial histological diagnosis was well-differentiated liposarcoma; however, subsequent molecular analysis showed no evidence of MDM2 amplification, suggesting a final diagnosis of benign lipoma. This case exemplifies diagnostic challenges in lipomatous retroperitoneal tumors, as well as the importance of inter-disciplinary collaboration in surgery to achieve the best surgical and oncological outcomes.